NEW YORK (GenomeWeb) – Agilent Technologies and Seahorse Bioscience announced after the close of the market on Wednesday that they have signed a definitive agreement under which Agilent will acquire Seahorse for $235 million in cash. 

Seahorse is based in Billerica, Massachusetts, and its technology enables scientists to better understand cell health, function, and signaling, as well as investigate the impact of the introduction of a specific drug on the cell by providing real-time kinetics "to unlock essential cellular bioenergetics data," the firms said. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.